Top 5 Diversified Bank Stocks To Own Right Now

The drop in share price yesterday, coupled with recent news regarding a new drug, has made this pharmaceutical giant look attractive again to MoneyShow's Jim Jubak.

The 2.51% drop in Pfizer (PFE) shares yesterday, February 5, plus recent news out of the company on trials for its experimental drug for breast cancer, Palbociclib, makes this Big Pharma stock an attractive dividend-income/capital appreciation story. The stock currently yields 3.39%.

On January 28, Pfizer announced fourth quarter earnings of 56 cents a share, 3 cents a share above Wall Street consensus. Revenue fell 2.4% year over year, but at $13.56 billion, still came in above the $13.41 billion consensus.

In the conference call, the company said it had implemented its plan to internally separate its operations into three units. Each of those units will begin to report results independently in 2014, in order to build a track record in preparation for a potential restructuring of the company, sometime, analysts speculate, around 2017.

Top Services Stocks To Watch For 2015: Salix Pharmaceuticals Ltd (SLXP)

Salix Pharmaceuticals, Ltd., incorporated on December 31, 2001, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�� products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

Xifaxan (rifaximin) tablets

Xifaxan is a gastrointestinal-specific oral antibiotic. The Food and Drug Administration ( FDA) approved Xifaxan 200 milligram for the treatment of patients 12 years of age and older with travelers��diarrhea caused by noninvasive strains of E coli. Xifaxan 550 milligram was approved by the FDA for reduction in risk of overt hepatic encephalopathy (HE), recurrence in patients 18 years of age or older.

It launched Xifaxan 200milligram in the United States and Xifaxan 550 milligram using its own direct sales force. The Company is exploring potential additional indications, formulations, clinical trials and co-promotion arrangements to capitalize on the potential for Xifaxan, including its development program in irritable bowel syndrome.

In October 2012, the USPTO declared an interference action to determine the priority of invention between Cipla�� application related to amorphous rifaximin and Solmag SpA�� application directed to amorphous rifaximin. In February 2012, the FDA posted draft bioequivalence guidance for rifaximin 550 milligram tablets. The draft guidance for rifaximin 550 milligram tablets recommends that in addition to conducting the program outlined in the FDA posted ! draft guidance document for rifaximin 200 milligram tablets discussed above, a single-dose, three-way crossover in-vivo study of fasting bioequivalence with pharmacokinetic endpoints in both fasting and fed states be performed in the 550 milligram tablets. Additionally, the guidance stipulated that the formulation of the 550 milligram strength should be proportionally similar to that of the 200 milligram strength in order to file an ANDA for approval of a generic rifaximin 550 milligram tablet for the treatment of hepatic encephalopathy.

MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid) oral solution

MoviPrep is a patent-protected, liquid polyethylene glycol-salt, or PEG, bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations.

Apriso (mesalamine) extended-release capsules 0.375 gram

Apriso is a locally-acting aminosalicylate and is the only delayed and extended release mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product�� prolonged release mechanism might allow them to expand the range of treatment options for ulcerative colitis.

Relistor (methylnaltrexone bromide)

Relistor Subcutaneous Injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved for use in over 55 countries worldwide.

OsmoPrep and Visicol (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) tablets

Visicol and OsmoPrep tablets are indicated for clean! sing of t! he colon as a preparation for colonoscopy in adults 18 years of age or older. Visicol and OsmoPrep are the only, tablet bowel cleansing products approved by the FDA and marketed in the United States. OsmoPrep is a patented, second-generation tablet bowel cleansing product that the FDA approved. OsmoPrep offers potential benefits compared to Visico,l such as its lack of microcrystalline cellulose, smaller tablet size and possible lower dose administration.

Solesta

Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for surgery or anesthesia.

Deflux

Deflux is a medical device indicated for children affected by Grades II-IV vesicoureteral reflux, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. Deflux was granted premarket approval application (PMA) approval, and has been on the market in the United States.

Fulyzaq (crofelemer) delayed-release tablets

On December 31, 2012, the FDA granted marketing approval for this product, under the trade name Fulyzaq. Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration.

Giazo (balsalazide disodium) tablets

February 3, 2012, the FDA granted marketing approval for this product under the trade name Giazo. Giazo is indicated for the treatment of mildly to moderately active ulcerative col! itis in m! ale patients 18 years of age and older. It shipped Giazo to wholesalers in 2012.

Metozolv ODT (metoclopramide hydrochloride) 5 milligrams and 10 milligrams orally disintegrating tablets

METOZOLV ODT is indicated for the relief of symptomatic gastroesophageal reflux or short-term (4-12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and diabetic gastroparesis or the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis.

Azasan (azathioprine) tablets

Azasan is an FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. It launched the 75 and 100 milligrams dosage strengths of Azasan in the United States.

Anusol-HC and Proctocort (hydrocortisone) creams and suppositories

The Company acquired the right to sell Anusol-HC 2.5% (hydrocortisone USP) cream, Anusol-HC 25 milligrams (hydrocortisone acetate) rectal suppositories, Proctocort 1% (hydrocortisone USP) cream and Proctocort 30 mg (hydrocortisone acetate) rectal suppositories from King Pharmaceuticals, Inc. The two cream products are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. The two suppository products are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions.

Pepcid (famotidine) for Oral Suspension and Diuril (Chlorothiazide)

Pepcid Oral Suspension is a widely known prescription pharmaceutical product indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and gastro-esophageal reflux disease. Pepcid Oral Suspension and Diuril Oral Suspension, both liquid form! ulations ! of their solid dosage form counterparts, compete in a combined annual United States market concentrated in pediatric and hospitalized patient populations.

Colazal (balsalazide disodium) capsules

The Company launched Colazal to physicians in the United States. FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with ulcerative colitis. The pediatric use of Colazal has been granted orphan drug designation. The Office of Generic Drugs, or OGD, approved three generic balsalazide capsule products.

The Company competes with GlaxoSmithKline plc, Giuliani S.p.A., Axcan Pharma, Inc., Abbott Laboratories, Warner Chilcott plc, Shire Pharmaceuticals Group plc, Pharmacia & Upjohn, Inc., Alaven Pharmaceutical LLC, Ferring Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Cumberland Pharmaceuticals, Inc, Prometheus Laboratories, Inc., Ranbaxy Pharmaceuticals, Ferndale Laboratories, GATE Pharmaceuticals , Nycomed , Medtronic, Inc., and Cubist Pharmaceuticals, Inc.

Advisors' Opinion:

• [By Garrett Cook]

  Salix Pharmaceuticals (NASDAQ: SLXP) shares tumbled 3.01 percent to $133.15 after the company agreed to merge with a unit of Cosmo Pharmaceuticals SpA.

• [By Paul Ausick]

  Stocks on the Move: Twitter Inc. (NYSE: TWTR) is down 7.3% at $41.64 on its second day of trading and word is that some hedge funds and traders are looking to borrow shares. Santarus Inc. (NASDAQ: SNTS) is up 37.6% at $31.95 after agreeing late Thursday night to an acquisition by Salix Pharmaceuticals Inc. (NASDAQ: SLXP) for $2.6 billion in cash.

• [By Philip Springer]

  What’s more, earnings estimates for 2014 by Wall Street analysts have increased for seven of the 10 companies over the last three months. Amgen’s are down slightly and those for Celgene and Novo Nordisk are unchanged.
  
  Two of the 10 stocks currently are in the PF Growth Portfolio. Another, Allergan, was sold for a 75 percent long-term gain since its initial recommendation.
  
  As of late February, the 10 stocks profiled carried market capitalizations of roughly $30 billion and up. Here are another four companies to watch: Grifols SA (NSDQ: GRFS), Jazz Pharmaceuticals PLC (NSDQ: JAZZ), Questcor Pharmaceuticals (NSDQ: QCOR) and Salix Pharmaceuticals (NSDQ: SLXP). Each of these four companies is generating rapid revenue and profit growth, and each stock carries a market capitalization of $5 billion or more.
  
  Have a happy and safe Fourth of July weekend!

Top 5 Diversified Bank Stocks To Own Right Now: Timeless Software Ltd (TLW)

Timeless Software Limited is an investment holding company mainly engaged in the provision of computer consultancy and software maintenance services, software development and sales of computer hardware and software. It operates in four divisions: software development, hardware sales, software sales and e-commerce services. As of March 31, 2012, the Company�� subsidiaries included Three Principles Computer Service Company Limited, which is engaged in the provision of computer consultancy services, development and sales of computer software; Encore Trading Limited, which is engaged in the trading of computer software and hardware and provision of information technology consultancy services in Hong Kong; Timeless Northern Software (Beijing) Company Limited, which is engaged in design, development and maintenance of computer software and systems, as well as provision of computer consultancy services, and other subsidiaries. Advisors' Opinion:

• [By Namitha Jagadeesh]

  IAG, the parent of British Airways, climbed 3 percent to 373.6 pence and Air France advanced 1.5 percent to 7.62 euros. BG Group Plc (BG/), the third-biggest oil and gas producer listed in the U.K., dropped 1.2 percent to 1,245 pence and Tullow Oil Plc (TLW) retreated 1.4 percent to 875 pence.

Top 5 Diversified Bank Stocks To Own Right Now: McMoRan Exploration Company (MMR)

McMoRan Exploration Co. engages in the exploration, development, production, and marketing of oil and natural gas in the shallow waters of the Gulf of Mexico and onshore in the Gulf Coast area of the United States. It is involved in lifting oil and natural gas to the surface; and gathering, treating, and processing hydrocarbons to extract liquids, such as ethane, propane, butane, and natural gasolines from natural gas. The company also provides exploration and production technologies, including the incorporation of 3-D seismic interpretation, offshore drilling to total depths, and horizontal drilling. As of December 31, 2012, it owned or controlled interests in 1,003 oil and gas leases in the Gulf of Mexico, and onshore Louisiana and Texas covering approximately 511,000 net acres. The company had estimated proved oil and natural gas reserves totaling 219.9 billion cubic feet equivalent. McMoRan Exploration Co. was founded in 1994 and is headquartered in New Orleans, Louisi ana.

Advisors' Opinion:

• [By Matt DiLallo]

  While it has diversity among metals, the company is also in the final stages of adding even more diversity among commodities. It has pending deals to acquire both McMoRan Exploration (NYSE: MMR  ) and Plains Exploration and Production (NYSE: PXP  ) . When the deals close, Freeport will shift its revenue mix from 100% mining related to around 75% mining and 25% oil and gas. That makes the company a truly diversified economic indicator as copper, oil, and natural gas are much more important to our economy than aluminum.

• [By David Smith]

  As we move into June, the company's attention is being directed to the combination of starting its huge Grasberg copper and gold facility in Indonesia, following a pair of accidents, and buttoning up its purchase of Houston-based energy producer Plains Exploration and Production Company. At the same time, its preparing to close on its planned acquisition of McMoRan Exploration (NYSE: MMR  ) , an event that's expected to occur early next week.

• [By David Smith]

  The pending purchases
  Aside from its current core metals operations, Freeport is in the process of acquiring a pair of independent oil and gas producers, Plains Exploration & Production (NYSE: PXP  ) and McMoRan Exploration (NYSE: MMR  ) . In December, Freeport announced that it would pay 0.6531 shares of its common stock and $25 in cash for each outstanding share of Plains. In addition, for McMoRan it stated that it would pay $14.75 in cash and 1.15 units of a royalty trust that will hold a 5% overriding royalty interest in McMoRan's shallow water and ultra-deepwater prospects.

• [By Rich Duprey]

  While there was a lot of grousing, the miner was returning to its roots as a multiline resources company -- it will also be purchasing McMoRan Exploration (NYSE: MMR  ) , a driller it had spun out in the 1990s -- after a series of mishaps and deadly accidents at its huge Grasberg mine, it could be the drilling operations that Freeport relies upon to see it through.

Top 5 Diversified Bank Stocks To Own Right Now: Coca-Cola Bottling Co. Consolidated(COKE)

Coca-Cola Bottling Co. Consolidated, together with its subsidiaries, engages in the production, marketing, and distribution of nonalcoholic beverages, primarily products of The Coca-Cola Company. The company offers sparkling beverages, such as energy drinks; and still beverages, including bottled water, tea, ready-to-drink coffee, enhanced water, juices, and sports drinks. It holds cola beverage agreements and allied beverage agreements, under which it produces, distributes, and markets sparkling beverage products of The Coca-Cola Company in certain regions. The company also distributes and markets still beverages of The Coca-Cola Company, such as POWERade, vitaminwater, and Minute Maid Juices To Go, as well as produces, distributes, and markets Dasani water products under still beverage agreements. In addition, it holds agreements to produce and market Dr Pepper. Further, the company distributes and markets various other products, including Monster energy productsand Sund rop, as well as its own products, such as Country Breeze tea, diet Country Breeze tea, and Tum-E Yummies, a vitamin C enhanced flavored drink, Bean & Body, and Simmer and Bazza energy tea. Additionally, it produces beverages for other Coca-Cola bottlers; and provides restaurants and other immediate consumption outlets with fountain products. The company sells and distributes its products directly to retail stores and other outlets, including food markets, institutional accounts, and vending machine outlets. It operates in North Carolina, South Carolina, south Alabama, South Georgia, middle Tennessee, western Virginia, and West Virginia. The company was founded in 1902 and is based in Charlotte, North Carolina.

Advisors' Opinion:

• [By Jesse Solomon]

  Other bellwethers scheduled to report earnings this week include Coca-Cola (COKE), Johnson & Johnson (JNJ, Fortune 500), and General Electric (GE, Fortune 500).

• [By Dan Dzombak]

  In the U.S., Coke announced that it will sell some of its internal bottling operations to its five U.S. independent bottlers: Coca-Cola Bottling Co. Consolidated (NASDAQ: COKE  ) , Coca-Cola Bottling Company United, Swire Coca-Cola USA, Coca-Cola Bottling Company High Country and Corinth Coca-Cola Bottling Works. No details were released, but the company did say it expects to close the deals in 2014.